TrialThe oncologist2024

Long-term safety of selpercatinib for Rearranged during transfection (RET)-activated advanced solid tumors in LIBRETTO-001: differing patterns of adverse events over time.

Luis E Raez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.